Correction to: An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to < 6 years with chronic kidney disease receiving dialysis

被引:0
|
作者
Winnie Y. Sohn
Anthony A. Portale
Isidro B. Salusky
Hao Zhang
Lucy L. Yan
Bella Ertik
Shahnaz Shahinfar
Edward Lee
Bastian Dehmel
Bradley A. Warady
机构
[1] Amgen,
[2] Inc.,undefined
[3] UCSF Benioff Children’s Hospital,undefined
[4] David Geffen School of Medicine at UCLA,undefined
[5] S. Shahinfar Consulting and Childrens Hospital of Philadelphia,undefined
[6] Children’s Mercy Hospital,undefined
来源
Pediatric Nephrology | 2019年 / 34卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The original version of this article unfortunately contained three mistakes. In Table 1, the last line under “Key Inclusion Criteria” should read “Normal or clinically acceptable ECGs at screening and at day − 1.” In addition, the abbreviation “IP” in the legend to Table 1 stands for “investigational product.”
引用
收藏
页码:739 / 740
页数:1
相关论文
共 50 条
  • [21] Pharmacokinetics and tolerability of rabeprazole sodium in subjects aged 12 to 16 years with gastroesophageal reflux disease: An open-label, single- and multiple-dose study
    James, Laura
    Walson, Philip
    Lomax, Kathleen
    Kao, Richard
    Varughese, Shanti
    Reyes, Josephine
    CLINICAL THERAPEUTICS, 2007, 29 (09) : 2082 - 2092
  • [22] A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function
    Ermer, James
    Corcoran, Mary
    Lasseter, Kenneth
    Marbury, Thomas
    Yan, Brian
    Martin, Patrick T.
    THERAPEUTIC DRUG MONITORING, 2016, 38 (04) : 546 - 555
  • [23] A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy
    Paller, A. S.
    Siegfried, E. C.
    Simpson, E. L.
    Cork, M. J.
    Lockshin, B.
    Kosloski, M. P.
    Kamal, M. A.
    Davis, J. D.
    Sun, X.
    Pirozzi, G.
    Graham, N. M. H.
    Gadkari, A.
    Eckert, L.
    Ruddy, M.
    Bansal, A.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (02) : 464 - 475
  • [24] An open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertension
    Simon, Marc A.
    Hanrott, Kate
    Budd, David C.
    Torres, Fernando
    Gruenig, Ekkehard
    Escribano-Subias, Pilar
    Meseguer, Manuel L.
    Halank, Michael
    Opitz, Christian
    Hall, David A.
    Hewens, Deborah
    Powley, William M.
    Siederer, Sarah
    Bayliffe, Andrew
    Lazaar, Aili L.
    Cahn, Anthony
    Rosenkranz, Stephan
    PULMONARY CIRCULATION, 2022, 12 (01)
  • [25] Phase 1, single-dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of etelcalcetide in pediatric patients with secondary hyperparathyroidism receiving hemodialysis
    Sohn, Winnie
    Salusky, Isidro B.
    Schmitt, Claus Peter
    Taylan, Christina
    Vande Walle, Johan
    Ngang, Jude
    Yan, Lucy
    Kroenke, Mark
    Warady, Bradley A.
    PEDIATRIC NEPHROLOGY, 2021, 36 (01) : 133 - 142
  • [26] Phase 1, single-dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of etelcalcetide in pediatric patients with secondary hyperparathyroidism receiving hemodialysis
    Winnie Sohn
    Isidro B. Salusky
    Claus Peter Schmitt
    Christina Taylan
    Johan Vande Walle
    Jude Ngang
    Lucy Yan
    Mark Kroenke
    Bradley A. Warady
    Pediatric Nephrology, 2021, 36 : 133 - 142
  • [27] Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with severe renal impairment: A single-dose, open-label, parallel-group study
    Gardin, Anne
    Dodman, Angela
    Kalluri, Sampath
    Neelakantham, Srikanth
    Tan, Xuemei
    Legangneux, Eric
    Shakeri-Nejad, Kasra
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2017, 55 (01) : 54 - 65
  • [28] A Phase 1, Open-label, Dose-escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1850 in Adults With Hypophosphatasia
    Dahir, Kathryn
    Dunn, Derek
    Hasan, Jawad
    Shannon, Amy
    Pan, Wei-Jian
    JOURNAL OF BONE AND MINERAL RESEARCH, 2023, 38 : 374 - 374
  • [29] A PHASE 1, OPEN-LABEL, DOSE-ESCALATING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ALXN1850 IN ADULTS WITH HYPOPHOSPHATASIA
    Dahir, K.
    Dunn, D.
    Mitter, S.
    Hasan, J.
    Shannon, A.
    Pan, W.
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2023, 35 : S43 - S44
  • [30] A Phase 1, Open-label, Dose-escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1850 in Adults With Hypophosphatasia
    Dahir, Kathryn
    Dunn, Derek
    Hasan, Jawad
    Shannon, Amy
    Pan, Wei-Jian
    JOURNAL OF BONE AND MINERAL RESEARCH, 2023, 38 : 70 - 70